Info Service on WTO and Trade Issues (Mar12/02)
13 March 2012
Third World Network
Dear friends and colleagues,
very pleased to share the news released by the Medecins Sans Frontieres
(MSF) Access Campaign in India that the Indian Patent Controller has
issued a compulsory licence on sorafenib tosylate, an important anti-cancer
medicine that covers the remaining period of the patent protection term,
until 2020. The decision that was made after hearings and the accompanying
documents are provided in web links below.
Third World Network
by MSF Access Campaign, India
India has just granted a CL to a generic company
The CL on sorafenib tosylate, the anti-cancer drug has been granted
to Natco Pharma till 2020 (balance of the patent term). Natco will be
required to pay 6% of net sales as royalty to Bayer. Natco's right to
manufacture and sell the drug is limited to the territory of India.
Background: In July 2011, NATCO, an Indian pharmaceutical company, applied
for a compulsory licence (CL) in the Mumbai patent office to manufacture
an affordable generic version of sorafenib tosylate – the anti-cancer
drug for which Bayer has obtained a patent IN215758 in India in 2008.
The patent expires in 2020.
In its CL application NATCO is proposing to market the same drug at
Rs. 8,800 per patient per month if the patent office grants it a compulsory
license. The price is likely to come down to 3% of what Bayer is charging.
Bayer currently markets the drug at a high price of approximately Rs.
2,80,000 per patient per month. This case is also important as it will
test Section 84 of the Indian Patent Act, under which the CL mechanism
kicks in when generic competitors request a CL.
Several hearing have been held by the Indian Patent Controller in the
last nine months. Bayer aggressively opposed and tried to delay the
grant of the CL. Now a decision granting a CL has been published today
by the Patent Office in India.
Under the WTO's TRIPS Agreement, CLs are a legally recognised means
to overcome barriers in accessing affordable medicines.
The CL documents and information regarding the hearings are available
Tel: 46573730/1, 9811365412
MAIN | ONLINE BOOKSTORE
| HOW TO ORDER